January 30, 2019
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Read More
January 30, 2019
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Read More
January 30, 2019
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Read More
January 30, 2019
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Read More
January 30, 2019
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Read More
January 30, 2019
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Read More
January 30, 2019
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Read More
December 10, 2018
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Read More
X